These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
463 related articles for article (PubMed ID: 31765822)
1. Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment? Yang P; Perlmutter JS; Benzinger TLS; Morris JC; Xu J Ageing Res Rev; 2020 Jan; 57():100994. PubMed ID: 31765822 [TBL] [Abstract][Full Text] [Related]
2. Dopamine D3 Receptor in Parkinson Disease: A Prognosis Biomarker and an Intervention Target. Xu J Curr Top Behav Neurosci; 2023; 60():89-107. PubMed ID: 35711029 [TBL] [Abstract][Full Text] [Related]
3. Dopamine D1 + D3 receptor density may correlate with parkinson disease clinical features. Yang P; Knight WC; Li H; Guo Y; Perlmutter JS; Benzinger TLS; Morris JC; Xu J Ann Clin Transl Neurol; 2021 Jan; 8(1):224-237. PubMed ID: 33348472 [TBL] [Abstract][Full Text] [Related]
4. Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits. Carnicella S; Drui G; Boulet S; Carcenac C; Favier M; Duran T; Savasta M Transl Psychiatry; 2014 Jun; 4(6):e401. PubMed ID: 24937095 [TBL] [Abstract][Full Text] [Related]
5. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse. Perfeito R; Cunha-Oliveira T; Rego AC Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292 [TBL] [Abstract][Full Text] [Related]
6. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake. Castro-Hernández J; Afonso-Oramas D; Cruz-Muros I; Salas-Hernández J; Barroso-Chinea P; Moratalla R; Millan MJ; González-Hernández T Neurobiol Dis; 2015 Feb; 74():325-35. PubMed ID: 25511804 [TBL] [Abstract][Full Text] [Related]
7. Current drug treatments targeting dopamine D3 receptor. Leggio GM; Bucolo C; Platania CB; Salomone S; Drago F Pharmacol Ther; 2016 Sep; 165():164-77. PubMed ID: 27343365 [TBL] [Abstract][Full Text] [Related]
8. Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions. Stoyka LE; Arrant AE; Thrasher DR; Russell DL; Freire J; Mahoney CL; Narayanan A; Dib AG; Standaert DG; Volpicelli-Daley LA Neurobiol Dis; 2020 Feb; 134():104708. PubMed ID: 31837424 [TBL] [Abstract][Full Text] [Related]
9. Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons. Bono F; Savoia P; Guglielmi A; Gennarelli M; Piovani G; Sigala S; Leo D; Espinoza S; Gainetdinov RR; Devoto P; Spano P; Missale C; Fiorentini C Mol Neurobiol; 2018 Feb; 55(2):1054-1067. PubMed ID: 28092083 [TBL] [Abstract][Full Text] [Related]
11. Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects. Albarrán-Bravo S; Ávalos-Fuentes JA; Cortés H; Rodriguez-Sánchez M; Leyva-García N; Rangel-Barajas C; Erlij D; Florán B Biomolecules; 2019 Sep; 9(9):. PubMed ID: 31480516 [TBL] [Abstract][Full Text] [Related]
12. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease. González H; Contreras F; Prado C; Elgueta D; Franz D; Bernales S; Pacheco R J Immunol; 2013 May; 190(10):5048-56. PubMed ID: 23589621 [TBL] [Abstract][Full Text] [Related]
13. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice. Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439 [TBL] [Abstract][Full Text] [Related]
14. Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease. Elgueta D; Aymerich MS; Contreras F; Montoya A; Celorrio M; Rojo-Bustamante E; Riquelme E; González H; Vásquez M; Franco R; Pacheco R Neuropharmacology; 2017 Feb; 113(Pt A):110-123. PubMed ID: 27693549 [TBL] [Abstract][Full Text] [Related]
16. The transfection of BDNF to dopamine neurons potentiates the effect of dopamine D3 receptor agonist recovering the striatal innervation, dendritic spines and motor behavior in an aged rat model of Parkinson's disease. Razgado-Hernandez LF; Espadas-Alvarez AJ; Reyna-Velazquez P; Sierra-Sanchez A; Anaya-Martinez V; Jimenez-Estrada I; Bannon MJ; Martinez-Fong D; Aceves-Ruiz J PLoS One; 2015; 10(2):e0117391. PubMed ID: 25693197 [TBL] [Abstract][Full Text] [Related]
17. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats. Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046 [TBL] [Abstract][Full Text] [Related]
18. TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson's disease. Kang SS; Zhang Z; Liu X; Manfredsson FP; Benskey MJ; Cao X; Xu J; Sun YE; Ye K Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10773-10778. PubMed ID: 28923922 [TBL] [Abstract][Full Text] [Related]
19. Reciprocal cross-sensitization of D1 and D3 receptors following pharmacological stimulation in the hemiparkinsonian rat. Lanza K; Chemakin K; Lefkowitz S; Saito C; Chambers N; Bishop C Psychopharmacology (Berl); 2020 Jan; 237(1):155-165. PubMed ID: 31435690 [TBL] [Abstract][Full Text] [Related]
20. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice. Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]